CN111212659B - Hpv疫苗 - Google Patents

Hpv疫苗 Download PDF

Info

Publication number
CN111212659B
CN111212659B CN201880053063.XA CN201880053063A CN111212659B CN 111212659 B CN111212659 B CN 111212659B CN 201880053063 A CN201880053063 A CN 201880053063A CN 111212659 B CN111212659 B CN 111212659B
Authority
CN
China
Prior art keywords
leu
sequence
asp
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880053063.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111212659A (zh
Inventor
L·多利尔
J·布莱特
A·雷耶斯-桑多瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CN111212659A publication Critical patent/CN111212659A/zh
Application granted granted Critical
Publication of CN111212659B publication Critical patent/CN111212659B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880053063.XA 2017-08-16 2018-08-16 Hpv疫苗 Active CN111212659B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1713163.2A GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine
GB1713163.2 2017-08-16
PCT/GB2018/052335 WO2019034887A1 (en) 2017-08-16 2018-08-16 HPV VACCINE

Publications (2)

Publication Number Publication Date
CN111212659A CN111212659A (zh) 2020-05-29
CN111212659B true CN111212659B (zh) 2023-09-22

Family

ID=59895974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880053063.XA Active CN111212659B (zh) 2017-08-16 2018-08-16 Hpv疫苗

Country Status (11)

Country Link
US (2) US11179456B2 (enExample)
EP (1) EP3668542A1 (enExample)
JP (1) JP7551495B2 (enExample)
KR (1) KR102713224B1 (enExample)
CN (1) CN111212659B (enExample)
AU (1) AU2018316734B2 (enExample)
CA (1) CA3072536A1 (enExample)
GB (1) GB201713163D0 (enExample)
MX (1) MX2020001655A (enExample)
SG (1) SG11202001244SA (enExample)
WO (1) WO2019034887A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114828878A (zh) * 2019-10-16 2022-07-29 癌症研究科技有限公司 用于癌症治疗的载体
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
WO2024218165A1 (en) * 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059325A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
PL2093410T3 (pl) * 2008-02-21 2014-07-31 Delphi Int Operations Luxembourg Sarl Wtryskiwacz paliwa z udoskonalonym układem sterującym działaniem zaworu
US20120141502A1 (en) 2009-04-20 2012-06-07 Eric Dixon Antibodies specific to e6 proteins of hpv and use thereof
US20150344529A1 (en) * 2012-12-25 2015-12-03 The Chemo-Sero-Therapeutic Research Institute Vaccine for hpv infection and/or hepatitis b comprising hpv/hbs chimeric protein as active ingredient
EA034056B1 (ru) 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059325A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Induction of Antitumor Immunity In vivo Following Delivery of a Novel HPV-16 DNA Vaccine Encoding an E6/E7 Fusion antigen;Jian Yan等;《Vaccine》;第431–440页 *
Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains;Krishna P. Singh等;《3 Biotech》;第1-10页 *
宫颈癌HPV基因疫苗研究进展;侯萌;《中国肿瘤生物治疗杂志》(第01期);第71-74页 *

Also Published As

Publication number Publication date
WO2019034887A1 (en) 2019-02-21
CN111212659A (zh) 2020-05-29
CA3072536A1 (en) 2019-02-21
US20220152189A1 (en) 2022-05-19
US11179456B2 (en) 2021-11-23
AU2018316734B2 (en) 2025-08-21
KR102713224B1 (ko) 2024-10-07
US20200306358A1 (en) 2020-10-01
GB201713163D0 (en) 2017-09-27
KR20200056384A (ko) 2020-05-22
SG11202001244SA (en) 2020-03-30
US12064477B2 (en) 2024-08-20
EP3668542A1 (en) 2020-06-24
JP2020536489A (ja) 2020-12-17
AU2018316734A1 (en) 2020-02-27
JP7551495B2 (ja) 2024-09-17
MX2020001655A (es) 2020-08-17

Similar Documents

Publication Publication Date Title
CN111212659B (zh) Hpv疫苗
KR102631985B1 (ko) 게놈을 변형시키기 위한 조성물 및 방법
KR102147007B1 (ko) Fad3 성능 유전자좌 및 표적화 파단을 유도할 수 있는 상응하는 표적 부위 특이적 결합 단백질
KR102357051B1 (ko) 신규 유전자 재조합 백시니아 바이러스
AU2021221448B2 (en) Modified plant
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
KR102700586B1 (ko) Hbv 백신
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
AU2017353868C1 (en) Synthetic chimeric poxviruses
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
KR20220031028A (ko) 아프리카 돼지 열병 백신
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
KR20220024508A (ko) 생물학적으로 봉쇄된 박테리아 및 그의 용도
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN111107872A (zh) 有用于癌症免疫疗法的牛痘病毒突变体
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
CN116670153A (zh) 允许在稳定细胞系中高效生长的非洲猪瘟疫苗的基因组缺失
AU2021102558A4 (en) Modified plant
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40000936B (zh) 新型基因重组牛痘病毒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant